Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
OBJECTIVE
To determine the tigecycline in-vitro susceptibility of naive gram-negative pathogens from serious infections in Delhi, India.


METHODS
During July to October 2007 investigations were carried out to determine the tigecycline in vitro susceptibility of 50 consecutive gram-negative pathogens from serious infections at the Sant Parmanand Hospital, Delhi, India. Minimum tigecycline inhibitory concentrations were determined employing the E test method (AB Biodisk).


RESULTS
Twenty-four percent of isolates were found to be tigecycline resistant or partly susceptible. Susceptibility of the isolates was lower than meropenem but similar to piperacillin-tazobactam, amoxicillin-clavulanic acid, and amikacin.


CONCLUSIONS
Tigecycline resistance was prevalent in the gram-negative isolates from serious infections prior to its marketing in India. The choice of any recently marketed antibiotic for a pilot treatment against serious gram-negative infections should not be automatic. In the initial phase of its marketing, it should be evaluated in parallel with the antibiotics with excellent local susceptibility profiles.
Arya
Subhash C
SC
Department of Microbiology and Infection Control, Sant Parmanand Hospital, Delhi, India. subhashji@hotmail.com
Agarwal
Nirmala
N
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline